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ABSTRACT
Research in human pluripotent stem cells, including
human embryonic stem cells (hESC) and human induced
pluripotent stem cells (hiPSC), is one of the most dynamic
research ﬁelds. Despite the high public attention, especially
for hESC research, there is only scattered information on
the number of hESC lines and the degree, dynamics, and
diversiﬁcation of their use on a global level. In this study
we present data on the current number of publicly dis-
closed hESC lines, on the extent and impact of experimen-
tal work involving hESCs, and on the use of speciﬁc hESC
lines in international research. The results are based on
the evaluation of nearly 1,000 research papers published
by the end of 2008, which describe experimental work on
hESCs, and of a comprehensive database of published
hESC lines. The average impact of hESC research papers
is high at 7.422, with a predominance of research output
by the United States. Of at least 1,071 original hESC lines
derived up to November 2009 at 87 institutions in 24 coun-
tries, only a fraction is thoroughly characterized. Our
data show the global predominance of a few hESC lines in
research, but also reveal remarkable country-speciﬁc dif-
ferences. Comparison of hESC and hiPSC application did
not show a diminished role for hESC research, but rather
revealed that, up to this time, both ﬁelds continue to
expand, exist independently, and partially overlap. STEM
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INTRODUCTION
Research with human embryonic stem cell (hESC) lines has
attracted increasing attention over the last decade because
these cells have the capability to proliferate indeﬁnitely and
to differentiate into any cell type of the body. On the other
hand, there has been much controversy about using hESCs
due to their origin from early human embryos, which resulted
in a wide panel of different national legislations on human
ESC research [1]. In a preceding report, we have determined
the number of hESC cell lines and quantiﬁed the extent of
experimental research involving hESCs [2], but since then
hESC research has further intensiﬁed and spread into many
more countries. The release of new National Institutes of
Health (NIH) guidelines on research involving hESCs in the
United States (http://stemcells.nih.gov/policy/2009guideli-
nes.htm) has evoked much interest in the question of how
many cell lines are available worldwide. However, to date
there is no current information on how many hESC lines
exist worldwide, and literature data on this question are
based on estimates and are somewhat divergent [3, 4].
Although there are now several registries that contain par-
tially overlapping data sets on a multitude of hESC lines [5–
7], the level of characterization of the cell lines listed in
these registries is highly variable and, most importantly, the
extent of their use in international research can not be
assessed. Moreover, there are no data that elucidate whether
there is a preferential use of certain cell lines in different
countries. We have determined the number of hESC lines
and analyzed the scale of hESC research on a global level,
including the use of speciﬁc hESC lines. We found remark-
able differences between countries. Our studies are based on
the analysis of a databank of hESC lines that was previously
described [2, 8] and has been updated regularly up to No-
vember 2009, as well as on the evaluation of nearly 1,000
research papers describing experimental work on hESCs up
to the end of 2008.
MATERIALS AND METHODS
The methods for extracting papers on experimental work on
hESCs and human induced pluripotent stem cells (hiPSCs) from
the PubMed database are given in the supporting information.
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RESULTS
Number of hESC Lines
We ﬁrst determined the number of hESC lines reported up
to November 24, 2009, in the scientiﬁc literature as well as
in stem cell registries, on web pages or in press releases.
According to our data, publicly available information exists
on at least 1,071 original hESC lines that were derived at
87 institutions in 24 countries (Table 1). For 694 of these
cell lines (64.8%), either derivation has been described in
English-language peer-reviewed journals or these cell lines
have been used in experimental work published in such
journals. For 590 cell lines, at least some characterization
data were reported in published articles. Thus, the number
of hESC lines reported in the scientiﬁc literature has mark-
edly increased since 2005, when only 171 of 414 known
hESC lines were reported in the scientiﬁc literature (2).
hESC lines not published in scientiﬁc journals to date com-
prise, for example, cell lines derived recently (e.g., 20
hESC lines from France and 17 lines from Denmark listed
in hESCreg, the hESC registry of the European Union, as
well as 68 lines in the United States, announced recently
by the NIH) and many cell lines derived at the Reproduc-
tive Genetics Institute in Chicago and distributed by Stemr-
ide International Limited. While characterization data for
the former will hopefully be published in the near term,
only little information is publicly available for many of the
hESC lines from the Reproductive Genetics Institute. More-
over, a large fraction of the hESC lines derived before Au-
gust 2001 and originally registered at the NIH has not
been described in the literature and is not publicly avail-
able for research so far.
When analyzing characteristics and speciﬁcities in deri-
vation modalities of hESC lines, two aspects should be
noted. First, among hESC lines publicly reported, at least
116 (10.8%) harbor genetic modiﬁcations linked to 33 inher-
itable human diseases (Table 2). These cell lines were usu-
ally derived from embryos examined by preimplantation
genetic diagnosis. By the end of 2005, only 27 of the 414

















Australia 19 3 14
Belgium 29 3 23
Brazil 1 1 0
Canada 4 2 2
China (including Taiwan) 236 13 228
Czech Republic 7 1 4
Denmark 31 4 14
Finland 10 2 5
France 20 4 0
India 15 5 5
Iran 6 1 6
Israel 14 3 12
Japan 3 1 3
Korea 37 5 35
Netherlands 4 1 4
Russia 16 2 5
Singapore 15 2 15
Spain 18 3 13
Sweden 90 3 45
Switzerland 1 1 1
Thailand 1 1 1
Turkey 18 1 7
UK 42 8 28
USA 434 17 224
Total 1,071 87 694
Given are the numbers of hESC lines derived in a speciﬁc
country, the number of institutions that reported successful
derivation of hESC lines, and the number of hESC lines reported
in peer-reviewed English-language journals. Note that hESC lines
derived at the Reproductive Genetics Institute (Chicago, IL),
which are partially distributed by Stemride International Limited,
were assigned to the United States. hESC lines from ES Cell
International were assigned to Singapore. Stem cell lines derived
from parthenogenetic embryos were not included. A detailed list
of the hESC lines is provided in the supporting information
material.
Table 2. Overview of hESC lines with genetic disorders linked to







Charcot-Marie tooth disease 1A (CMT1A) 2
Cystic ﬁbrosis (CF) 15
Dystrophya myotonica type 1 (DM1) 6
Fabry syndrome 1
Facioscapulohumeral (FSH) muscular dystrophy 9
Familial adenomatous polyposis (FAP) 3
Familial breast cancer 1
Fanconi anaemia 1
Fragile X syndrome (FX) 9
Hemophilia A 1
Huntington’s disease (HD) 11
Marfan syndrome (MFS) 4
Multiple endocrine neoplasia, type 1 2
Multiple endocrine neoplasia, type 2 4
Muscular dystrophy, type Becker 1
Muscular dystrophy, type Duchenne 4
Muscular dystrophy, type Emery Dreifuss 4
Myotubular myopathy (MTM), cross-linked 2
Neuroﬁbromatosis type 1 7
Ocular albinism 2
Osteogenesis imperfecta type 1 1
Pelizaeus-Merzbacher disease (PMLD) 1
Popliteal Pterygium syndrome (PPS) 1
Sandhoff disease 3
Sickle cell anaemia 3
Spinal muscular atrophy type 1 (SMA1) 2
Spinocerebellar ataxia type 2 (SCA2) 1
Spinocerebellar ataxia type 7 (SCA7) 1
Torsion dystonia (DYT1) 2
Tuberous sclerosis 3
Total 116
Note that one hESC line harbours two genetic alterations linked
to inheritable diseases.
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tions linked to an inheritable human disease [2]. Thus, there
has been a considerable increase in this fraction of hESC
lines over the past 4 years. When compared to recently pub-
lished ﬁgures [9], the number of reported ‘‘diseased’’ hESC
lines even doubled. This highlights the outstanding interest
in this type of hESC lines, because they might be a valuable
tool for studying the pathomechanisms of genetically inher-
itable diseases [10, 11]. Second, although xeno-free deriva-
tion of hESC lines was considered to be a crucial prerequi-
site for later clinical use [12], only a few hESC lines were
produced without any exposure to animal-derived com-
pounds or in accordance with standards of good manufactur-
ing practice. However, many cell lines were derived on
human feeder cells, without performing immune surgery or
under conditions free of animal-derived serum. A detailed
list of the hESC lines reported here is provided as support-
ing information. In addition, there is a multitude of hESC
sublines, some of which have been applied frequently, such
as the sublines H9.2 of H9 (WiCell Research Institute, Inc.,
Madison, WI, http://www.wicell.org), ENVY of HES-3
(ESI, ES Cell International Pte Ltd, Singapore, http://
www.escellinternational.com), or SA002.5 of Sahlgrenska
002 (Cellartis AB, Go ¨teburg, Sweden, http://www.cellartis.-
com), which were not considered separately in the present
analysis.
Number and Impact of Publications Regarding
Experimental Work Involving hESC
Next, we analyzed the number and impact of scientiﬁc papers
published by the end of 2008 and describing results of hESC
derivation and experimental work involving hESCs. We per-
formed a broad search of the PubMed database for papers
describing hESC work according to the method described ear-
lier (for details, see also supporting information methods),
which resulted in nearly 6,000 initial hits. These results were
manually evaluated to exclude those papers in which hESCs
were not experimentally used (e.g., comments, reviews, news,
editorials, work on mouse ES cells, papers on ethical or polit-
ical aspects of hESC research, etc.). We further excluded
articles that summarized previously described methods and
protocols, as well as papers in which only hESC-derived
materials (e.g., DNA, RNA, or protein extracts) were used.
Work involving stem cell lines derived from parthenogenetic
embryos was also excluded from the analysis. Finally, we
identiﬁed a total of 989 hESC research papers from 27 coun-
tries published between 1998 and 2008 in English-language
peer-reviewed journals (a complete list of papers is provided
in the supporting information). As shown in Table 3, most of
these 989 research papers originated from groups in the
United States (41.1%), followed by the United Kingdom
(9.5%), Israel (7.2%), Korea (6.2%), and Singapore (5.6%).
The leading position of US research in the hESC ﬁeld has
remained nearly unchanged as approximately 40% of publica-
tions in this ﬁeld were from groups based in the United States
over the last 6 years, although the total extent of this research
increased dramatically worldwide (Fig. 1).
Because the number of papers does not necessarily reﬂect
the impact of research, we also determined the Institute for
Science Information citation impact factor for journals that
published those 989 papers. The weighted overall average 5-
year impact factor (2004–2008) for journals that had pub-
lished experimental hESC work was 7.422, indicating the out-
standing interest in hESC research. However, hESC work
from US-based groups was published in journals with a higher
average impact factor (9.123). The same is true for work
published by Canadian groups (10.769), while work from
Chinese, Korean, and Swedish groups were published in less
inﬂuential journals (average 5-year impact factors of 4.041,
4.425, and 4.768, respectively). Because the impact factor of
a journal does not necessarily reﬂect the impact or quality of
individual papers published in this journal [13], we also deter-
mined citation frequencies for said 989 papers (supporting in-
formation). According to these data, hESC papers published
between 2000 and 2007 were cited on average 14.9 times by
studies published in 2008. However, studies from US and











China (including Taiwan) 43 4.3





















United Kingdom 94 9.5
United States 406 41.1
Total 989 100
Search of the PubMed database and paper selection were
performed according to the method described in the supporting
information. Assignment of papers to a country was according to
the address of the corresponding author. Note that 56 hESC
research papers that were published online ahead of print in 2008
but were printed in 2009 are not included. A detailed paper list
is provided as supporting information.
Figure 1. Share of published hESC research from selected countries
in the total number of research papers published 2003–2008 world-
wide in English language journals.
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17.4 citations in 2008, respectively), while work from Chi-
nese, Korean, and Swedish groups were cited less frequently
(6.7, 7.1, and 8.1 times in 2008, respectively). Moreover,
among the 20 hESC research papers cited most frequently in
the scientiﬁc literature in 2008, ﬁfteen (75%) were from
groups in the United States, and US groups were involved in
two others (supporting information). These ﬁndings extend
and conﬁrm our own earlier results on the leadership of US
research in the hESC ﬁeld [2, 8].
hiPSCs show many, if not all, characteristics of hESCs,
but production of hiPSC lines does not require the destruction
of human embryos. Additionally, potential clinical use of au-
tologous hiPSCs might not be hindered by immunological
problems inherent to allogeneic hESC-derived cells. Since the
ﬁrst description of hiPSCs in 2007, it was speculated that
research using hiPSCs may replace hESC research in the near
term, and that hESCs would only be needed for comparison
in the future. Some researchers involved in cloning and hESC
research even claimed to concentrate solely on hiPSC
research in the future [14]. Therefore, we considered to what
extent research involving hiPSCs and hESCs would overlap
and whether there were indications that hESC research would
decline. In a ﬁrst step toward investigating this question, we
analyzed the number of papers describing experimental work
involving hiPSCs by applying the same criteria as for experi-
mental hESC studies and using the search string described in
the supporting information. Of 16 hiPSC research papers
extracted by our search of 2008 publications, 14 (87.5%) also
reported application of hESCs or hESC-derived materials. In
2009, the number of experimental hiPSC studies published in
English-language peer-reviewed journals dramatically
increased to 66 (preliminary data for January 1 to September
30, 2009). Of these studies, 47 (71.2%) also involved applica-
tion of hESCs or hESC-derived materials. The number of ex-
perimental hESC studies for the same period was 342 (prelim-
inary data for January 1 to September 30, 2009) showing a
further expansion of international hESC research in 2009.
These ﬁndings allow for the conclusion that, at least in 2008
and 2009, both research ﬁelds existed independently, were
further extended, and partially overlap. Moreover, the vast
majority of studies on hESCs published in 2009 did not
involve hiPSCs but, conversely, research on hiPSCs partially
involved the application of hESCs or hESC-derived materials.
Use of hESC Lines in International Research
Finally, we were interested to determine the use of hESC lines
in international research. A complete and detailed list on the
hESC lines used in scientiﬁc studies investigated here is pro-
vided as supporting information. Of 989 papers, 964 contained
information on the speciﬁc hESC lines used. As shown in Fig-
ure 2A, most international hESC research published between
1998 and 2008 was performed with hESC lines provided by
WiCell, which were derived in 1998 by Thomson and col-
leagues [15], or derivatives thereof. In 53.8% of all hESC
studies published by end of 2008, at least one WiCell line or a
derivative of such a line was used either without (36.3%) or
with (17.5%) cell lines from other producers. Cell lines from
Figure 2. Use of hESC lines of selected providers in international research and in published research from selected countries. A: The share of
cell lines from a speciﬁc provider in the cell lines used overall in hESC research papers published 1998–2008. BresaGen, BresaGen, Inc., Athens,
Georgia; Cellartis, Cellartis AB, Go ¨teburg, Sweden; ESI, ES Cell International Pte Ltd, Singapore; HSCI, Harvard Stem Cell Institute, Massachu-
setts; Technion, Israel Institute of Technology, Haifa, Israel; UCSF, University of California San Francisco, California; WiCell, WiCell Research
Institute, Madison, Wisconsin. Cell lines from other providers contain hESC lines from 48 providers such as Karolinska Institute, Stockholm,
Sweden (3.4%); Seoul National University, Seoul, Korea (3.0%); Kyoto University, Japan (2.4%); University of Newcastle, United Kingdom
(1.8%); and University of Shefﬁeld, United Kingdom (1.3%). Note that in many studies more than one hESC line was used. B: The percentage
of hESC papers from a speciﬁc country produced with cell lines of the given providers. Cell lines from providers other than those speciﬁcally
named were grouped in ‘‘other providers.’’
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signiﬁcant country-speciﬁc differences in the use of hESC cell
lines from certain providers (Fig. 2B). Whereas 75% of US-
based research was performed with at least one WiCell line,
only a small percentage of papers originating from Australia,
Korea, or Sweden (which together account for more than 14%
of hESC research papers) was based on these hESC lines
(1.8%, 3.3%, and 4.8%, respectively). More than 80% of
hESC research published by Australian groups was performed
with hESC lines of ESI. Similarly, work reported by Swedish
groups was mainly performed with hESC lines from Cellartis
AB and from another Swedish provider, Karolinska Institute.
Korean groups nearly exclusively used hESC lines provided
by Korean producers. In Japan, Singapore, and China, 16.7%,
40%, and 46.7% of reported research was exclusively or par-
tially performed with WiCell lines, respectively (Fig. 2B),
whereas a large portion of hESC work was performed with
hESC lines derived in the respective country. For example, 23
of 31 hESC research papers from Japanese groups reported
work performed with hESC lines provided by Kyoto Univer-
sity. These lines have not been used outside Japan for legal
reasons.
In contrast, all hESC research reported from Germany by
the end of 2008 was performed involving hESC lines from
WiCell (data not shown). Although hESC research is strictly
regulated in Germany by the Stem Cell Act, it was permitted
to use any of the hESC lines originally registered at the NIH.
Therefore, it seems unlikely that the preferential use of just
the WiCell lines is only due to a restrictive stem cell research
policy. This view is supported by the fact that a high percent-
age of hESC work was also based on WiCell lines in coun-
tries with a highly permissive hESC research policy, such as
Great Britain and Canada (74.5% and 90%, respectively).
Moreover, we wished to determine whether the wide use
of WiCell lines could be a direct consequence of a possible
interdependence of international hESC research, which could
lead to an indirect transmission of US stem cell research poli-
cies to collaborative research in other countries. We therefore
performed an analysis of authors’ afﬁliations in the 989
research papers investigated here. This analysis revealed that,
even in those countries with predominant use of WiCell lines,
only a relatively low percentage of hESC papers evolved
from direct collaboration with US groups (Canada, 20%;
Israel, 13.1%; United Kingdom, 10.6%). Similarly, only 22%
of hESC work published by US groups was the result of a
direct collaboration with groups outside the United States.
Of all hESC lines reported in the literature by the end of
2008, H9 and H1 (including their derivatives) were the most
frequently used (36.7% and 30.8% of published studies,
respectively) (Table 4). In published research from US
groups, these two cell lines were used even more often
(52.6% and 47.4% of hESC publications, respectively). We
therefore wondered whether the preferential use of these two
cell lines over other NIH-approved cell lines might be a con-
sequence of preferential NIH funding. This seems not to be
the case. According to information from the 989 papers inves-
tigated here, 69.1% and 70.9% of studies performed with
hESC lines H1 and H9 in the US had NIH or other govern-
mental funding. Similarly, publications based on work with
two other NIH approved cell lines frequently used in the
United States (BG01 and UC06) were funded by the NIH to a
comparable degree (72.8% and 81.5%, respectively).
On the other hand, our data show that non-WiCell lines
have also been widely used. For example, the Harvard Stem
Cell Institute (HSCI) line HUES9, which has been available
for only 5 years, was used in more than 7% of experimental
hESC work published in 2008. Overall, cell lines from HSCI
have been used in 12.3% and 12.9% of published work from
15 countries in 2007 and 2008, respectively, indicating diver-
siﬁcation of cell lines used in international hESC research.
DISCUSSION
In this study, we have analyzed the scale and impact of hESC
research on a global level, including the use of hESC lines.
We found evidence for at least 1,071 original hESC lines, a
large portion of which has been reported in the scientiﬁc liter-
ature so far. However, despite this multitude of hESC lines,
only cell lines from a few providers have been extensively
used in published international research, with remarkable dif-
ferences between countries.
Although we found evidence for more than 1,000 supposed
hESC lines, the number of available and well-characterized
lines is probably considerably lower. It even remains an open





















H9 WiCell 363 36.7 89 39.2 111 37.4
H1 WiCell 305 30.8 71 31.3 85 28.6
H7 WiCell 101 10.2 18 7.9 25 8.4
BG01 Bresagen 85 8.6 21 9.2 19 6.4
HES-3 ESI 76 7.7 20 8.8 19 6.4
HES-2 ESI 63 6.4 15 6.6 18 6.1
HSF-6 UCSF 57 5.8 15 6.6 12 4.0
BG02 BresaGen 45 4.6 9 4.0 7 2.4
HUES9 HSCI 37 3.7 14 6.2 21 7.1
HUES7 HSCI 32 3.2 12 5.3 13 4.3
I6 Technion 32 3.2 8 3.5 6 2.0
Shown is the number of papers (published 1998–2008) that report on the derivation or experimental use of the particular hESC line. Data for
2007 and 2008 are also listed separately. The percentage values present the share of publications using the particular cell lines in the total
number of publications in the given period. Note that in many studies more than one hESC line was used. Sublines were allocated to the
respective parental hESC line.
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entiﬁc literature have all the characteristics of human pluri-
potent cell lines and are available for research. For example,
characterization data in scientiﬁc articles are often only pre-
sented exemplarily for individual cell lines, whereas deriva-
tion of multiple cell lines was reported. Furthermore, more
than 400 hESC lines were described or used in only a single
study with no follow-up studies so far. On the other hand,
our list contains several as yet unpublished hESC lines with
characteristics of true human pluripotent stem cells. For
example, there are 14 hESC lines that were not published in
the scientiﬁc literature until the end of 2008, but were
accepted by the United Kingdom stem cell bank, which
requires a speciﬁc level of characterization. Similarly, 68
hESC lines derived at institutions in the United States and
not reported in the literature so far have been announced for
NIH registration between September and November 2009. It
is most likely that these cell lines will also have characteris-
tics of truly pluripotent cells. Moreover, several companies,
such as Cellartis, Novocell, or Advanced Cell Technology,
Inc. with extensive experience in hESC research have
reported the existence of hESC lines for which no characteri-
zation data have yet been published in the scientiﬁc litera-
ture. Some cell lines from Russia and China have obviously
been well-characterized but only published in Russian or
Chinese language journals, respectively. Therefore, it remains
difﬁcult to determine the number of well-characterized and
available hESC lines. While the International Stem Cell Initi-
ative characterized 59 hESC lines from 17 countries and was
able to derive common and robust molecular patterns as a
step toward the standardization of these cells [3], the actual
level of characterization for most hESC lines is highly vari-
able, often incomplete in accessible registries, and thus of
limited value for comparison.
We also analyzed the extent and impact of international
research involving hESCs. By 2008, the number of hESC
research papers had more than tripled compared to the pe-
riod from 1998 to 2005 [2]. In the same period, the average
impact factor of journals in which original hESC work was
published increased from 6.03 to 7.422. Thus, the high aver-
age impact factor of hESC research is probably not a mere
consequence of the novelty of the hESC ﬁeld but rather
reﬂects a continuous and spreading interest in this type of
research. Our data also underscore the leading position of
the United States in hESC research with respect to quantity
and quality of this research, which remained unchanged over
the last decade. Other studies found an increasing productiv-
ity gap in US hESC research and an underperformance of
US research in the ﬁeld, respectively [16, 17]. The reasons
for the differing assessments may be partially due to a dif-
ferent data pool used. For example, Levine [17] included in
his analysis all journal articles citing the ﬁrst hESC paper
by Thomson et al. [15] and therefore might have included
articles that do not report original hESC work but rather
summaries of or reﬂections on work with hESC cells. On
the other hand, many more recent hESC research papers do
not cite Thomson et al. [8]. In contrast, we have extensively
analyzed all articles extracted by our analysis and even
excluded papers describing previously reported work in
articles published in rather methodical journals such as Na-
ture Protocols, Stem Cell Protocols,o rMethods in Molecu-
lar Biology.
Our data further reveal the preferential use of only a few
cell lines in international hESC research until the end of
2008. We found a pronounced predominance of cell lines pro-
vided by the WiCell Research Institute, which was even
stronger in US-based studies. However, our data also uncover
regional differences in the use of hESC lines. The reasons
for this phenomenon are not clear, and explanations remain
speculative. For example, the low usage of WiCell lines in
Australia, Korea, or Sweden might be due to the fact that
these countries had their own hESC lines available at the
start of international hESC research in the early years of this
decade. On the other hand, the high percentage in use of
WiCell lines in work from Great Britain and Canada may be
explained by the early need of cells for hESC work in these
countries before the later availability of domestic stem cell
lines. The preferential use of WiCell lines in hESC studies
from Israel (64.8% of research papers despite the early avail-
ability of their own hESC lines) might be due to the involve-
ment of Israeli scientists in the derivation of the ﬁrst WiCell
lines and the establishment of well-suited sublines of H9 in
Israel. However, a considerable portion of studies from
Israel did not contain information on the speciﬁc cell lines
used.
Importantly, we did not ﬁnd proof for a direct correlation
between the nature of a country’s stem cell research policy
(restrictive versus permissive) and the use of certain hESC
lines nor for an indirect transmission of US stem cell policies
to other regions due to highly collaborative research. Thus,
other factors, such as early publicity by the provider or by
early users, distribution policy, or the grade of characteriza-
tion and documentation of a cell line (which increases with
the frequency of its use), might contribute to the decision for
using a speciﬁc cell line.
While this manuscript was in preparation, Scott et al.
published a study on the use of human embryonic stem
cell lines [18]. The authors found a strong predominance of
only two hESC lines, WiCell H1 and H9, in experimental
hESC research. This ﬁnding was based on the number of
requests for certain hESC lines to the NIH Stem Cell Bank
and to the HSCI, and on the evaluation of 534 publications
for which hESC lines were used. Unfortunately, it is not
obvious from this study whether it was focused on the US
situation only or also included hESC work from other
countries. Moreover, it is not clear what literature data
pool was used for this analysis. Although our data, in prin-
ciple, conﬁrm the ﬁnding on the predominance of WiCell
lines, there are also major differences to those reported by
Scott et al. For example, these authors found that 83.3%
and 60.9% of all hESC studies were based on the H9 and
H1 cell lines, respectively, whereas we found evidence for
application of these cell lines and their derivatives in
36.7% and 30.8% of hESC studies worldwide, respectively.
This discrepancy is most likely due to a more comprehen-
sive data set used in our study. Whether the US stem cell
policies and resulting NIH funding restrictions are responsi-
ble for the preferred use of just two WiCell lines still
remains an open question.
In summary, our data provide a detailed picture on the
status of international hESC research based on a systematic
analysis of the entire peer-reviewed literature. The persistent
dominance of the WiCell lines H1 and H9 in research also
points to a potential weakness with respect to universal
applicability of the results, standardization, and harmoniza-
tion in the ﬁeld. The collection and dissemination of a wide
range of data, including negative data, for as many hESC
lines as possible (for example, by international registries
such as hESCreg, the European Human Embryonic Stem Cell
Registry) may be one option for the diversiﬁcation of hESC
use. International registries may then provide the answer to
researchers as to whether it makes a difference which cell
line to use, or to choose the best cell line for their research
or application.
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